Skye Bioscience Inc (SKYE) Stock Price, Quote & News

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 410 0266

Website: skyebioscience.com

Address:

11250 El Camino Real, Suite 100, San Diego, United States

YazzJr Jul. 14 at 6:38 PM

$SKYE Unfortunately this move downward in on relatively high volume approaching half a million shares. Hmmm. Looks like somebody is dumping.

1 · Reply

Fellforit Jul. 14 at 6:12 PM

$SKYE hold on...it'll be buyin' time again..

0 · Reply

LosersMakeMillions Jul. 14 at 11:01 AM

$BATL $EONR $SKYE $TPET $TURB 🤷🏽‍♀️😁🚀🌙

1 · Reply

Fellforit Jul. 13 at 11:54 PM

$SKYE pennies have been discontinued Jack..but i'm sure your millions of shares amount to some dollars!! Good Luck...

0 · Reply

MissionaryTrader Jul. 13 at 5:55 PM

$SKYE added

1 · Reply

Deng42 Jul. 12 at 11:13 PM

$SKYE $AMZE $MMA $SPY

1 · Reply

MissionaryTrader Jul. 10 at 6:41 PM

$SKYE pretty big add for someone

3 · Reply

Merlintrader Jul. 10 at 6:25 PM

Obesity drugs radar $VKTX $GPCR $SKYE - three clinical-stage weight-loss stocks to watch (Viking, Structure, Skye) https://www.merlintrader.com/obesity-drug-stocks-vktx-gpcr-skye-2026/

0 · Reply

MissionaryTrader Jul. 10 at 2:56 PM

$SKYE ASK is curious

0 · Reply

Blinddartthrowerl Jul. 10 at 2:18 AM

$SKYE What you guys think Puneet drives? I say a Tesla Cyber truck

0 · Reply

Skye Bioscience Transcript: AGM 2026

May 20, 2026, 7:00 AM EDT - 2 months ago

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 12, 2026, 1:33 PM EDT - 2 months ago

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

2026-05-12T11:22:30.000Z - 2 months ago

Skye Bioscience price target lowered to $6 from $13 at Piper Sandler

2026-05-11T21:09:20.000Z - 2 months ago

Skye Bioscience reports Q1 EPS (32c), consensus (32c)

May 11, 2026, 4:01 PM EDT - 2 months ago

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026, 4:00 PM EDT - 2 months ago

Skye Bioscience Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Skye Bioscience Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 2 months ago

Skye Bioscience Slides: Corporate presentation

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 7, 2026, 7:00 AM EDT - 3 months ago

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 3, 2026, 7:00 AM EDT - 3 months ago

Skye Bioscience Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 3 months ago

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Mar 10, 2026, 4:30 PM EDT - 4 months ago

Skye Bioscience Earnings Call Transcript: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 4 months ago

Skye Bioscience Earnings release: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 4 months ago

Skye Bioscience Annual report: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 4 months ago

Skye Bioscience Slides: Q4 2025

2026-03-10T20:12:08.000Z - 4 months ago

Skye Bioscience reports Q4 EPS (36c), consensus (31c)

Mar 10, 2026, 4:01 PM EDT - 4 months ago

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 7:00 AM EST - 4 months ago

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Feb 21, 2026, 6:00 AM EST - 5 months ago

Skye Bioscience Slides: Corporate presentation

2026-02-02T12:26:39.000Z - 5 months ago

Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab

Feb 2, 2026, 7:00 AM EST - 5 months ago

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

2026-01-29T12:20:16.000Z - 5 months ago

Skye Bioscience presents poster on efficacy of Nimacimab

Jan 29, 2026, 7:00 AM EST - 5 months ago

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 6 months ago

Skye Bioscience to Present Poster at Keystone Obesity Conference

2026-01-12T12:12:34.000Z - 6 months ago

Skye Bioscience provides 2026 corporate outlook

Jan 12, 2026, 7:00 AM EST - 6 months ago

Skye Provides 2026 Corporate Outlook

2026-01-05T12:25:09.000Z - 6 months ago

Skye Bioscience, Halozyme enter collaboration, license agreement

HALO

2026-01-05T12:11:01.000Z - 6 months ago

Halozyme, Skye Bioscience announce global collaboration, license agreement

HALO

Jan 5, 2026, 7:00 AM EST - 6 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Dec 19, 2025, 2:56 PM EST - 7 months ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 8, 2025, 7:11 AM EST - 7 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 4, 2025, 11:30 AM EST - 7 months ago

Skye Bioscience Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 12:55 PM EST - 7 months ago

Skye Bioscience Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 7:00 AM EST - 8 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 10, 2025, 4:30 PM EST - 8 months ago

Skye Bioscience Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Skye Bioscience Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Skye Bioscience Quarterly report: Q3 2025

2025-11-10T21:16:34.000Z - 8 months ago

Skye Bioscience reports Q3 EPS (32c), consensus (32c)

Nov 10, 2025, 4:01 PM EST - 8 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

2025-11-05T12:52:20.000Z - 9 months ago

Skye Bioscience to present topline data from CBeyond on nimacimab

Nov 5, 2025, 7:05 AM EST - 9 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:00 AM EST - 9 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Oct 28, 2025, 8:00 AM EDT - 9 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

2025-10-06T16:15:27.000Z - 10 months ago

Skye Bioscience downgraded to Hold from Buy at Craig-Hallum

2025-10-06T14:35:58.000Z - 10 months ago

Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-06T14:20:06.000Z - 10 months ago

Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-06T12:19:20.000Z - 10 months ago

Why Is Skye Bioscience Stock Down 60% Today?

Oct 6, 2025, 8:00 AM EDT - 10 months ago

Skye Bioscience Transcript: Study Update

Oct 6, 2025, 8:00 AM EDT - 10 months ago

Skye Bioscience Press release: Study Update

Oct 6, 2025, 8:00 AM EDT - 10 months ago

Skye Bioscience Slides: Study Update

2025-10-06T11:16:16.000Z - 10 months ago

Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study

Oct 6, 2025, 7:09 AM EDT - 10 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:00 AM EDT - 10 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Sep 19, 2025, 7:00 AM EDT - 10 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 11 months ago

Skye Bioscience Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:00 AM EDT - 11 months ago

Skye Bioscience Slides: Corporate Presentation

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Skye Bioscience Transcript: KOL Event

Sep 4, 2025, 7:00 AM EDT - 11 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 2, 2025, 7:00 AM EDT - 11 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 21, 2025, 7:00 AM EDT - 11 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Slides: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

YazzJr Jul. 14 at 6:38 PM

$SKYE Unfortunately this move downward in on relatively high volume approaching half a million shares. Hmmm. Looks like somebody is dumping.

1 · Reply

Fellforit Jul. 14 at 6:12 PM

$SKYE hold on...it'll be buyin' time again..

0 · Reply

LosersMakeMillions Jul. 14 at 11:01 AM

$BATL $EONR $SKYE $TPET $TURB 🤷🏽‍♀️😁🚀🌙

1 · Reply

Fellforit Jul. 13 at 11:54 PM

$SKYE pennies have been discontinued Jack..but i'm sure your millions of shares amount to some dollars!! Good Luck...

0 · Reply

MissionaryTrader Jul. 13 at 5:55 PM

$SKYE added

1 · Reply

Deng42 Jul. 12 at 11:13 PM

$SKYE $AMZE $MMA $SPY

1 · Reply

MissionaryTrader Jul. 10 at 6:41 PM

$SKYE pretty big add for someone

3 · Reply

Merlintrader Jul. 10 at 6:25 PM

Obesity drugs radar $VKTX $GPCR $SKYE - three clinical-stage weight-loss stocks to watch (Viking, Structure, Skye) https://www.merlintrader.com/obesity-drug-stocks-vktx-gpcr-skye-2026/

0 · Reply

MissionaryTrader Jul. 10 at 2:56 PM

$SKYE ASK is curious

0 · Reply

Blinddartthrowerl Jul. 10 at 2:18 AM

$SKYE What you guys think Puneet drives? I say a Tesla Cyber truck

0 · Reply

MissionaryTrader Jul. 9 at 3:28 PM

$SKYE added

1 · Reply

YazzJr Jul. 9 at 1:41 PM

$SKYE Man it's been too quiet from this company. No PR, no updates, no Instagrams from the CEO. Hopefully something of substance soon.

2 · Reply

BillionerOfKing Jul. 7 at 12:19 AM

$SKYE Current Stock Price: $0.71 Contracts to trade: $2.5 SKYE Jul 17 2026 Call Entry: $0.05 Exit: $0.09 ROI: 91% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Fellforit Jul. 6 at 8:34 PM

$SKYE anybody have change for a penny?

1 · Reply

TheMoneyDude777 Jul. 6 at 11:49 AM

$SKYE yes please keep buying lol so they can do more dilution so keep buying.

0 · Reply

MissionaryTrader Jul. 2 at 8:12 PM

$SKYE Happy 250th

0 · Reply

Fellforit Jun. 30 at 11:46 PM

$SKYE wow--really driving the sp missh. keep buying, within eyesight now!

0 · Reply

MissionaryTrader Jun. 29 at 6:58 PM

$SKYE added

1 · Reply

Blinddartthrowerl Jun. 27 at 10:55 PM

$SKYE The reason Puneet gets so many shares as compensation is so after the RS he still has a decent amount of shares left for the next pump and dump Their next trick is they will have some insider buy $40,000 worth of shares - he must know something right I read they have 8 patients in the trials lol - probably Puneets grandma and cousins Let me guess no one got sick in the 1st study so now they can increase the dose in the next trial sometime in 2027 Dude should change his name to Puneet Villian See you guys back on the penny stock exchange

1 · Reply

Blinddartthrowerl Jun. 27 at 10:26 PM

$SKYE RS should be this week I think Missionary man is Aircray

0 · Reply

Polsky Jun. 27 at 12:09 PM

$SKYE Are we good here folks? loool

0 · Reply

Maxandbear Jun. 27 at 10:59 AM

$SKYE i had this stock lost big. There are better companies to invest in.

0 · Reply

Market Cap	23.27M
Revenue (ttm)	0.00
Net Income (ttm)	-55.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	90,481
Avg Vol	165,984
Day's Range	N/A - N/A
Shares Out	35.14M
Stochastic %K	34%
Beta	2.94
Analysts	Strong Sell
Price Target	$7.71